Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

Core Points - The company held its first meeting of the 11th Board of Directors on June 20, 2025, where several key resolutions were passed [1][2][3][4][5][6]. Group 1: Board Elections and Appointments - Chen Jiao was elected as the Chairwoman of the 11th Board of Directors and will serve as the legal representative of the company [1]. - The members of the specialized committees under the 11th Board of Directors were elected, including the Strategy and ESG Committee, Audit Committee, Compensation and Assessment Committee, and Nomination Committee [2]. - Liu Wei was reappointed as the Chief Executive Officer, while Chen Jiao was reappointed as the Executive President [3]. - Other senior executives, including Liu Jia, Xiong Jianfeng, and Feng Bo, were also reappointed as Senior Vice Presidents [3][4]. Group 2: Compensation and Management Structure - The compensation scheme for senior management was approved, with the Compensation and Assessment Committee responsible for performance evaluations [4]. - Mei Xue was appointed as the Securities Affairs Representative [5]. Group 3: International Expansion Plans - The Board authorized management to initiate preparations for issuing H shares and listing on the Hong Kong Stock Exchange to enhance the company's international competitiveness and financing capabilities [5][6]. - KPMG was proposed as the auditing firm for the H share issuance [6]. Group 4: Upcoming Shareholder Meeting - The company announced the 5th extraordinary general meeting of shareholders to be held on July 16, 2025 [6].

Meeting Overview - The shareholders' meeting of Jiadu Technology Group Co., Ltd. was held on June 30, 2025, in Guangzhou [1] - The meeting was convened by the board of directors and chaired by Chairman Liu Wei, complying with the Company Law and Articles of Association [1][4] Voting Results - All non-cumulative voting proposals were approved with significant support, including: - Proposal 1: 98.54% approval from A-shareholders [1] - Proposal 2: 96.17% approval from A-shareholders [1] - Proposal 3: 96.17% approval from A-shareholders [1] - Cumulative voting proposals also received strong backing, with: - Proposal for director Gu Qingyang's election receiving majority support [2] Shareholder Participation - The meeting saw a high level of participation, with A-shareholders voting overwhelmingly in favor of the proposals, indicating strong shareholder confidence [2][3] Legal Compliance - The meeting's procedures, including the qualifications of conveners and attendees, as well as the voting process, were deemed legal and valid by the attending lawyers [4]

Core Viewpoint - The legal opinion letter confirms the legality and validity of the procedures, qualifications, and voting results of the 2025 Fourth Extraordinary General Meeting of Jiadu Technology Group Co., Ltd. [1][4][7] Meeting Procedures - The meeting was convened by the company's board of directors and announced on June 14, 2025, via the Shanghai Stock Exchange website, detailing the time, location, and agenda [2][3]. - The meeting was held on June 30, 2025, combining on-site and online voting methods, with specific time slots for online voting [3][4]. Attendance and Voting Rights - A total of 520 shareholders participated in the meeting, representing 448,719,542 shares, which is 21.1039% of the total voting shares [5]. - The meeting's attendees included company directors, supervisors, and senior management, all of whom met the legal qualifications for participation [5][6]. Voting Results - The following resolutions were passed: - Change of registered capital: 442,173,252 votes in favor, 6,404,890 against [6]. - Amendment of the Articles of Association: 431,515,863 votes in favor, 17,088,979 against [6]. - Revision of shareholder meeting rules: 431,537,363 votes in favor, 17,058,979 against [6]. - Revision of board meeting rules: 431,534,763 votes in favor, 17,060,479 against [6]. - Revision of cumulative voting implementation details: 431,543,463 votes in favor, 17,059,779 against [6]. - Revision of profit distribution management system: 430,125,716 votes in favor, 18,453,526 against [6]. - Approval of the board of directors' remuneration plan: 440,711,205 votes in favor, 7,851,437 against [6]. - Authorization for the board to manage equity in affiliated companies: 430,127,316 votes in favor, 18,469,626 against [6]. - Election of the 11th board of directors with high approval rates [6][7]. Conclusion - The legal opinion concludes that the meeting's procedures, qualifications of attendees, and voting results comply with relevant laws and regulations, confirming their legality and validity [7][8].

Group 1 - The core viewpoint of the articles highlights the successful initial operation of Guangzhou Metro Line 10 and Line 12, with Jiadu Technology playing a crucial role as a key partner in providing integrated smart solutions for the metro systems [1][3] - Jiadu Technology has developed a smart operation control platform that integrates over 20 subsystems from different vendors, enabling intelligent operational assistance through features like video inspection, passenger flow warning, and emergency response [1][2] - The implementation of facial recognition technology allows passengers to experience seamless access with a recognition delay of less than 0.3 seconds, enhancing the overall passenger experience [1][2] Group 2 - The introduction of AI-driven solutions for precise passenger flow management addresses the challenges of high passenger volumes at major hubs, providing essential technical support for optimizing capacity and dynamic alerts [2] - Both new lines utilize the highest level of automation (GoA4), marking a historic breakthrough in Guangzhou's rail transit, with upgrades to the platform door systems ensuring safety and efficiency [2] - Jiadu Technology aims to continue collaborating with Guangzhou Metro to develop more smart and efficient transportation lines, contributing to the broader development of the Greater Bay Area [3]

Company Announcements - Jihua Group's existing product system does not involve brain-computer interface related fields [1] - Prit's plan to invest 1 billion yuan to build a plastic modification materials headquarters and R&D manufacturing base in South China [1][2] - Lian De Equipment won a contract worth 157 million yuan for BOE's 8.6 generation AMOLED production line project [1][2] - Jiadu Technology plans to issue shares (H-shares) overseas and list on the Hong Kong Stock Exchange [1][2] - Longdi Group intends to acquire no more than 20.1667% equity in Jujia Technology [1][4] - New Zhonggang plans to repurchase shares worth 40 million to 80 million yuan [1][4] - Xiaogoods City expects a net profit increase of 12.57% to 17.40% in the first half of the year [1][4] - Sinopec Capital plans to reduce its holdings by no more than 3.5256 million shares in Haizheng Materials through block trading [1][4] - Lihua Co., Ltd. intends to reduce its holdings by no more than 3.00% [1][4] - Zhimin Da plans to raise no more than 213 million yuan through a private placement [1][5] - Xiangtong Co. plans to issue corporate bonds not exceeding 4 billion yuan [1][5] Performance Forecasts - Hanyu Pharmaceutical expects a half-year profit of 142 million to 162 million yuan, turning a profit compared to the previous year [4] - Taotao Automotive anticipates a net profit increase of 70.34% to 97.81% in the first half of the year [4] - Weichai Heavy Machinery expects a net profit increase of 40% to 60% in the first half of the year [4] Shareholding Changes - Lihua Co., Ltd.'s actual controller Cheng Lili and his concerted actors plan to reduce their holdings by no more than 3.00% [4] - He Shi Eye Hospital's Advanced Manufacturing Fund plans to reduce its holdings by no more than 2% [4] - Haitan Ruisheng's shareholder He Lin and his concerted actors plan to reduce their holdings by no more than 2.9463% [4] - Sinopec Capital plans to reduce its holdings by no more than 3.5256 million shares in Haizheng Materials [4] Other Announcements - Zhimin Da plans to raise no more than 213 million yuan through a private placement [5] - Yuyuan Co. plans to issue corporate bonds not exceeding 40 billion yuan [5] - Jinhongshun has terminated the planning of a major asset restructuring [5]

证券代码：600728 证券简称：佳都科技 公告编号：2025-062 佳都科技集团股份有限公司 关于聘请公司发行 H 股股票并在香港联合交易所有限公司 上市审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内 容的真实性、准确性和完整性承担个别及连带责任。 佳都科技集团股份有限公司（以下简称"公司"）于 2025 年 6 月 30 日召开公司第十一届 董事会第一次会议，审议通过了《关于聘请公司发行 H 股股票并在香港联合交易所有限公司 上市审计机构的议案》，同意公司聘请毕马威会计师事务所（以下简称"毕马威香港"）为公司 发行 H 股股票并在香港联合交易所有限公司主板挂牌上市（以下简称"本次 H 股上市"）的 审计机构。具体情况如下： 一、拟聘会计师事务所事项的情况说明 考虑到毕马威香港在境外发行上市项目方面拥有较为丰富的财务审计经验，具备足够的独 立性、专业能力，经过综合考量和审慎评估，公司董事会决定聘请毕马威香港为本次 H 股上 市的审计机构。该事项尚需提交公司股东会审议。 二、拟聘会计师事务所的基本信息 (一)机构信息 1、基本信息 毕马威香港为一所根 ...

佳都科技集团股份有限公司（以下简称"公司"）于 2025 年 6 月 30 日召开公司第十一届 董事会第一次会议，审议通过了《关于授权公司管理层启动公司境外发行股份（H 股）并在香 港联合交易所有限公司上市相关筹备工作的议案》，现将有关情况公告如下： 证券代码：600728 证券简称：佳都科技 公告编号：2025-061 佳都科技集团股份有限公司 关于授权公司管理层启动公司境外发行股份（H 股）在香港联 合交易所有限公司上市相关筹备工作的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内 容的真实性、准确性和完整性承担个别及连带责任。 为进一步提高公司综合竞争力，提升公司国际品牌形象，加快公司国际化战略的实施及海 外业务布局，增强公司的境外融资能力，根据公司总体发展战略及运营需要，公司拟在境外发 行股份（H 股）并在香港联合交易所有限公司（以下简称"香港联交所"）上市（以下简称"本 次 H 股上市"）。公司董事会同意授权公司管理层启动本次 H 股上市的相关前期筹备工作。 公司计划与相关中介机构就本次 H 股上市的具体推进工作进行商讨，关于本次 H 股上市的 具 ...

佳都科技集团股份有限公司 关于选举职工董事的公告 证券代码：600728 证券简称：佳都科技 公告编号：2025-059 1 / 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《中华人民共和国公司法》等相关法律法规以及《佳都科技集团股份有限公 司章程》的规定，经佳都科技集团股份有限公司（以下简称"公司"）工会委员会召 开全体委员会议，选举张利连女士为公司第十一届董事会职工董事。张利连女士将与 公司股东会选举产生的新一届董事会成员共同组成公司第十一届董事会，任期同第十 一届董事会。 特此公告。 佳都科技集团股份有限公司董事会 2025 年 6 月 30 日 附：张利连女士简历 张利连女士，1971 年 6 月生，电子科技大学管理硕士，2008 年起先后任佳都集团 审计总监、财务中心总经理、副总裁等管理岗位，2010 年 6 月至 2011 年 5 月担任佳都 科技监事会主席，现任佳都科技副总裁兼人力行政中心总经理，2021 年 3 月 31 日至 2025 年 6 月 30 日担任公司监事会主席。 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于佳都科技集团股份有限公司 2025 年第四次临时股东大会的 法律意见书 国枫律股字[2025]A0345 号 致：佳都科技集团股份有限公司（贵公司） 北京国枫律师事务所（以下称"本所"）接受贵公司的委托，指派律师出席并见证 贵公司 2025 年第四次临时股东大会（以下称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下称"《公司法》"）、《中华人民 共和国证券法》（以下称"《证券法》"）、《上市公司股东会规则》（以下称"《股 东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下称"《证券法律业务管理 办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下称"《证券法律业务执业 规则》"）等相关法律、行政法规、规章、规范性文件及《佳都科技集团股份有限公司章 程》（以下称"《公司章程》"）的规定，就本次会议的召集与召开程序、召集人资格、出 席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对 ...